Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Miguel Zugman, et al. on X:
“Long-term follow-up of TIVO-3 highlights key findings in CPI-treated mRCC:
- PFS benefit: Tivozanib 7.3 vs. Sorafenib 5.1 months (HR 0.55)
- OS trend: HR 0.69, favoring tivozanib (18.1 vs. 20.9 months)
- Durable response: Tivozanib DOR 20.3 vs. Sorafenib 5.7 months
- Safety: Lower VEGF-TKI-related grade ≥3 AEs vs. sorafenib”
Authors: Miguel Zugman, et al.
